C15ORF23 expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 2.815000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
3.618800E-01
Normal-vs-Stage2
2.661200E-01
Normal-vs-Stage3
5.654600E-01
Normal-vs-Stage4
6.730800E-01
Stage1-vs-Stage2
5.045000E-01
Stage1-vs-Stage3
8.245400E-01
Stage1-vs-Stage4
5.895400E-01
Stage2-vs-Stage3
4.613200E-01
Stage2-vs-Stage4
3.323400E-01
Stage3-vs-Stage4
8.046400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
2.593600E-01
Normal-vs-AfricanAmerican
7.576400E-01
Normal-vs-Asian
3.742600E-01
Caucasian-vs-AfricanAmerican
2.020800E-01
Caucasian-vs-Asian
5.495700E-02
AfricanAmerican-vs-Asian
5.742600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
2.730800E-01
Normal-vs-Female
2.978800E-01
Male-vs-Female
9.011200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
4.341400E-01
Normal-vs-Age(41-60Yrs)
2.223400E-01
Normal-vs-Age(61-80Yrs)
3.283600E-01
Normal-vs-Age(81-100Yrs)
2.418000E-01
Age(21-40Yrs)-vs-Age(41-60Yrs)
9.610800E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
5.668200E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
7.954000E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
6.158100E-02
Age(41-60Yrs)-vs-Age(81-100Yrs)
5.655600E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
6.262600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
3.748400E-01
Normal-vs-Daily Drinker
3.253800E-01
Normal-vs-Weekly Drinker
3.227800E-01
Normal-vs-Occasional Drinker
1.846580E-01
Normal-vs-Social Drinker
2.303400E-01
Non Drinker-vs-Daily Drinker
9.920400E-01
Non Drinker-vs-Weekly Drinker
9.878800E-01
Non Drinker-vs-Occasional Drinker
8.642000E-01
Non Drinker-vs-Social Drinker
9.964400E-01
Daily Drinker-vs-Weekly Drinker
9.945400E-01
Daily Drinker-vs-Occasional Drinker
8.796000E-01
Daily Drinker-vs-Social Drinker
9.960000E-01
Weekly Drinker-vs-Occasional Drinker
8.919600E-01
Weekly Drinker-vs-Social Drinker
9.906400E-01
Occasional Drinker-vs-Social Drinker
8.657800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
6.985200E-01
Normal-vs-Grade 2
8.256400E-01
Normal-vs-Grade 3
9.378000E-01
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
5.64109999999785E-05
Grade 1-vs-Grade 3
3.64360000000286E-05
Grade 1-vs-Grade 4
6.985200E-01
Grade 2-vs-Grade 3
4.727600E-02
Grade 2-vs-Grade 4
8.256400E-01
Grade 3-vs-Grade 4
9.378000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
4.321800E-01
Normal-vs-NonDiabetic
2.270400E-01
Diabetic-vs-NonDiabetic
2.883800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
3.049600E-02
Normal-vs-NoPancreatitis
2.941600E-01
Pancreatitis-vs-NoPancreatitis
3.022000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
1.647840E-01
Normal-vs-N1
2.829000E-01
N0-vs-N1
3.295600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
3.396000E-02
Normal-vs-TP53-NonMutant
2.670000E-01
TP53-Mutant-vs-TP53-NonMutant
2.53359999979885E-07
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
